Transdermal absorptive drug formulation
US5602165A · kind A · utility
0Cited by
2References
10Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | May 10, 1994 |
| Grant date | Feb 11, 1997 |
| Priority date | — |
| Expiry date | May 10, 2014 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61P11/00
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
A transdermal absorptive drug formulation containing 3-isobutyryl-2-isopropylpyrazolo [1,5-a ]pyridine as active ingredient effective for bronchial asthma and cerebrovascular disorder is provided. The formulation affords excellent sustained releasing and long acting characteristics with substantially reduced side-effects such as nausea and vomitting.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.